Evidence map›Paper›PMID 33080897›Full record

ReviewMolecules (Basel, Switzerland)2020

Current Status of Matrix-Assisted Laser Desorption/Ionization-Time-of-Flight Mass Spectrometry (MALDI-TOF MS) in Clinical Diagnostic Microbiology.

Sachio Tsuchida, Hiroshi Umemura, Tomohiro Nakayama

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Rapid identification of Sporothrix brasiliensis by MALDI-TOF MS directly from clinical cultures in an Amazonian epidemic setting.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Complete genome sequence ofMicrobiology resource announcements · 2026
    Article
  14. Article
  15. Co-evolution of resistance and virulence inFrontiers in cellular and infection microbiology · 2026
    Review
  16. Article
  17. Article
  18. Article
  19. Environmental monitoring and equipment sanitation to mitigateApplied and environmental microbiology · 2025
    Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sachio TsuchidaDivisions of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Hiroshi UmemuraDivisions of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Tomohiro NakayamaDivisions of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass spectrometry (MS), a core technology for proteomics and metabolomics, is currently being developed for clinical applications. The identification of microorganisms in clinical samples using matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) is a representative MS-based proteomics application that is relevant to daily clinical practice. This technology has the advantages of convenience, speed, and accuracy when compared with conventional biochemical methods. MALDI-TOF MS can shorten the time used for microbial identification by about 1 day in routine workflows. Sample preparation from microbial colonies has been improved, increasing the accuracy and speed of identification. MALDI-TOF MS is also used for testing blood, cerebrospinal fluid, and urine, because it can directly identify the microorganisms in these liquid samples without prior culture or subculture. Thus, MALDI-TOF MS has the potential to improve patient prognosis and decrease the length of hospitalization and is therefore currently considered an essential tool in clinical microbiology. Furthermore, MALDI-TOF MS is currently being combined with other technologies, such as flow cytometry, to expand the scope of clinical applications.

Indexed as

ProteomicsBacterial InfectionsHumansMetabolomicsMicrobiological TechniquesMicrobiologySpecimen HandlingSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionizationbacterial identificationblood cultureclinical proteomicsmatrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF MS), sample preparation

Identifiers

PMID33080897
PMCPMC7587594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.